Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Work In Process (2020 - 2025)

Puma Biotechnology (PBYI) has disclosed Work In Process for 6 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Work In Process rose 77.18% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Dec 2025, up 77.18%, and an annual FY2025 reading of $1.3 million, up 77.18% over the prior year.
  • Work In Process was $1.3 million for Q4 2025 at Puma Biotechnology, down from $5.4 million in the prior quarter.
  • Across five years, Work In Process topped out at $7.8 million in Q2 2024 and bottomed at $758000.0 in Q4 2024.
  • Average Work In Process over 5 years is $2.5 million, with a median of $2.0 million recorded in 2024.
  • Peak annual rise in Work In Process hit 169.08% in 2025, while the deepest fall reached 82.89% in 2025.
  • Year by year, Work In Process stood at $1.4 million in 2021, then surged by 92.13% to $2.7 million in 2022, then tumbled by 69.18% to $820000.0 in 2023, then decreased by 7.56% to $758000.0 in 2024, then surged by 77.18% to $1.3 million in 2025.
  • Business Quant data shows Work In Process for PBYI at $1.3 million in Q4 2025, $5.4 million in Q3 2025, and $1.3 million in Q2 2025.